Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 421

1.

Infections, Vaccines and Autoimmunity: A Multiple Sclerosis Perspective.

Jakimovski D, Weinstock-Guttman B, Ramanathan M, Dwyer MG, Zivadinov R.

Vaccines (Basel). 2020 Jan 28;8(1). pii: E50. doi: 10.3390/vaccines8010050. Review.

2.

Longitudinal analysis of cerebral aqueduct flow measures: multiple sclerosis flow changes driven by brain atrophy.

Jakimovski D, Zivadinov R, Weinstock-Guttman B, Bergsland N, Dwyer MG, Lagana MM.

Fluids Barriers CNS. 2020 Jan 31;17(1):9. doi: 10.1186/s12987-020-0172-3.

3.

Recovery of cognitive function after relapse in multiple sclerosis.

Benedict RH, Pol J, Yasin F, Hojnacki D, Kolb C, Eckert S, Tacca B, Drake A, Wojcik C, Morrow SA, Jakimovski D, Fuchs TA, Dwyer MG, Zivadinov R, Weinstock-Guttman B.

Mult Scler. 2020 Jan 23:1352458519898108. doi: 10.1177/1352458519898108. [Epub ahead of print]

PMID:
31971066
4.

A multimodal approach to assess the validity of atrophied T2-lesion volume as an MRI marker of disease progression in multiple sclerosis.

Tavazzi E, Bergsland N, Kuhle J, Jakimovski D, Ramanathan M, Maceski AM, Tomic D, Hagemeier J, Kropshofer H, Leppert D, Dwyer MG, Weinstock-Guttman B, Benedict RHB, Zivadinov R.

J Neurol. 2019 Nov 25. doi: 10.1007/s00415-019-09643-z. [Epub ahead of print]

PMID:
31768628
5.

Tagged cine magnetic resonance imaging to quantify regional mechanical changes after acute myocardial infarction.

Karthikeyan B, Sonkawade SD, Pokharel S, Preda M, Schweser F, Zivadinov R, Kim M, Sharma UC.

Magn Reson Imaging. 2019 Oct 24. pii: S0730-725X(19)30245-0. doi: 10.1016/j.mri.2019.09.010. [Epub ahead of print]

PMID:
31668928
6.

Serum neurofilament light chain level associations with clinical and cognitive performance in multiple sclerosis: A longitudinal retrospective 5-year study.

Jakimovski D, Zivadinov R, Ramanthan M, Hagemeier J, Weinstock-Guttman B, Tomic D, Kropshofer H, Fuchs TA, Barro C, Leppert D, Yaldizli Ö, Kuhle J, Benedict RH.

Mult Scler. 2019 Oct 15:1352458519881428. doi: 10.1177/1352458519881428. [Epub ahead of print]

PMID:
31610732
7.

Targeting Iron Dyshomeostasis for Treatment of Neurodegenerative Disorders.

Bergsland N, Tavazzi E, Schweser F, Jakimovski D, Hagemeier J, Dwyer MG, Zivadinov R.

CNS Drugs. 2019 Nov;33(11):1073-1086. doi: 10.1007/s40263-019-00668-6.

PMID:
31556017
8.

Atrophied Brain T2 Lesion Volume at MRI Is Associated with Disability Progression and Conversion to Secondary Progressive Multiple Sclerosis.

Genovese AV, Hagemeier J, Bergsland N, Jakimovski D, Dwyer MG, Ramasamy DP, Lizarraga AA, Hojnacki D, Kolb C, Weinstock-Guttman B, Zivadinov R.

Radiology. 2019 Nov;293(2):424-433. doi: 10.1148/radiol.2019190306. Epub 2019 Sep 24.

PMID:
31549947
9.

Teriflunomide's effect on humoral response to Epstein-Barr virus and development of cortical gray matter pathology in multiple sclerosis.

Zivadinov R, Ramanathan M, Hagemeier J, Bergsland N, Ramasamy DP, Durfee J, Kolb C, Weinstock-Guttman B.

Mult Scler Relat Disord. 2019 Nov;36:101388. doi: 10.1016/j.msard.2019.101388. Epub 2019 Sep 9.

PMID:
31525628
10.

Lipoprotein(a) Levels Are Associated with the Size of Extracranial Arteries in Multiple Sclerosis.

Jakimovski D, Zivadinov R, Pelizzari L, Browne RW, Weinstock-Guttman B, Ramanathan M.

J Vasc Res. 2020;57(1):16-23. doi: 10.1159/000502115. Epub 2019 Sep 5.

PMID:
31487715
11.

Preserved network functional connectivity underlies cognitive reserve in multiple sclerosis.

Fuchs TA, Benedict RHB, Bartnik A, Choudhery S, Li X, Mallory M, Oship D, Yasin F, Ashton K, Jakimovski D, Bergsland N, Ramasamy DP, Weinstock-Guttman B, Zivadinov R, Dwyer MG.

Hum Brain Mapp. 2019 Dec 15;40(18):5231-5241. doi: 10.1002/hbm.24768. Epub 2019 Aug 24.

PMID:
31444887
12.

Serum neurofilament light chain levels associations with gray matter pathology: a 5-year longitudinal study.

Jakimovski D, Kuhle J, Ramanathan M, Barro C, Tomic D, Hagemeier J, Kropshofer H, Bergsland N, Leppert D, Dwyer MG, Michalak Z, Benedict RHB, Weinstock-Guttman B, Zivadinov R.

Ann Clin Transl Neurol. 2019 Sep;6(9):1757-1770. doi: 10.1002/acn3.50872. Epub 2019 Aug 22. Erratum in: Ann Clin Transl Neurol. 2019 Dec;6(12):2607.

13.

Plasma levels of protein C pathway proteins and brain magnetic resonance imaging volumes in multiple sclerosis.

Ziliotto N, Zivadinov R, Baroni M, Marchetti G, Jakimovski D, Bergsland N, Ramasamy DP, Weinstock-Guttman B, Straudi S, Manfredini F, Ramanathan M, Bernardi F.

Eur J Neurol. 2020 Feb;27(2):235-243. doi: 10.1111/ene.14058. Epub 2019 Sep 8.

PMID:
31408242
14.

Cholesterol and neurodegeneration: longitudinal changes in serum cholesterol biomarkers are associated with new lesions and gray matter atrophy in multiple sclerosis over 5 years of follow-up.

Murali N, Browne RW, Fellows Maxwell K, Bodziak ML, Jakimovski D, Hagemeier J, Bergsland N, Weinstock-Guttman B, Zivadinov R, Ramanathan M.

Eur J Neurol. 2020 Jan;27(1):188-e4. doi: 10.1111/ene.14055. Epub 2019 Aug 19.

PMID:
31369181
15.

High-density lipoprotein cholesterol is associated with multiple sclerosis fatigue: A fatigue-metabolism nexus?

Browne RW, Jakimovski D, Ziliotto N, Kuhle J, Bernardi F, Weinstock-Guttman B, Zivadinov R, Ramanathan M.

J Clin Lipidol. 2019 Jul - Aug;13(4):654-663.e1. doi: 10.1016/j.jacl.2019.06.003. Epub 2019 Jun 18.

PMID:
31307953
16.

Cumulative gadodiamide administration leads to brain gadolinium deposition in early MS.

Zivadinov R, Bergsland N, Hagemeier J, Ramasamy DP, Dwyer MG, Schweser F, Kolb C, Weinstock-Guttman B, Hojnacki D.

Neurology. 2019 Aug 6;93(6):e611-e623. doi: 10.1212/WNL.0000000000007892. Epub 2019 Jul 8.

PMID:
31285398
17.

Salient Central Lesion Volume: A Standardized Novel Fully Automated Proxy for Brain FLAIR Lesion Volume in Multiple Sclerosis.

Dwyer MG, Bergsland N, Ramasamy DP, Weinstock-Guttman B, Barnett MH, Wang C, Tomic D, Silva D, Zivadinov R.

J Neuroimaging. 2019 Sep;29(5):615-623. doi: 10.1111/jon.12650. Epub 2019 Jul 1.

PMID:
31259467
18.

Response heterogeneity to home-based restorative cognitive rehabilitation in multiple sclerosis: An exploratory study.

Fuchs TA, Ziccardi S, Dwyer MG, Charvet LE, Bartnik A, Campbell R, Escobar J, Hojnacki D, Kolb C, Oship D, Pol J, Shaw MT, Wojcik C, Yasin F, Weinstock-Guttman B, Zivadinov R, Benedict RHB.

Mult Scler Relat Disord. 2019 Sep;34:103-111. doi: 10.1016/j.msard.2019.06.026. Epub 2019 Jun 22.

PMID:
31254960
19.

Network Dynamics and Cognitive Impairment in Multiple Sclerosis: Functional MRI-based Decoupling of Complex Relationships.

Zivadinov R, Dwyer MG.

Radiology. 2019 Aug;292(2):458-459. doi: 10.1148/radiol.2019191125. Epub 2019 Jun 25. No abstract available.

PMID:
31237815
20.

Trait Conscientiousness predicts rate of brain atrophy in multiple sclerosis.

Fuchs TA, Benedict RH, Wilding G, Wojcik C, Jakimovski D, Bergsland N, Ramasamy DP, Weinstock-Guttman B, Zivadinov R, Dwyer MG.

Mult Scler. 2019 Jun 20:1352458519858605. doi: 10.1177/1352458519858605. [Epub ahead of print]

PMID:
31219390
21.

Decrease in Secondary Neck Vessels in Multiple Sclerosis: A 5-year Longitudinal Magnetic Resonance Angiography Study.

Jakimovski D, Topolski M, Kimura K, Pandya V, Weinstock-Guttman B, Zivadinov R.

Curr Neurovasc Res. 2019;16(3):215-223. doi: 10.2174/1567202616666190612111127.

PMID:
31195944
22.

No association between variations in extracranial venous anatomy and clinical outcomes in multiple sclerosis patients over 5 years.

Gandhi S, Marr K, Mancini M, Caprio MG, Jakimovski D, Chandra A, Hagemeier J, Hojnacki D, Kolb C, Weinstock-Guttman B, Zivadinov R.

BMC Neurol. 2019 Jun 11;19(1):121. doi: 10.1186/s12883-019-1350-2.

23.

Ventral posterior substantia nigra iron increases over 3 years in Parkinson's disease.

Bergsland N, Zivadinov R, Schweser F, Hagemeier J, Lichter D, Guttuso T Jr.

Mov Disord. 2019 Jul;34(7):1006-1013. doi: 10.1002/mds.27730. Epub 2019 Jun 10.

PMID:
31180615
24.

Cognitive Profiles of Aging in Multiple Sclerosis.

Jakimovski D, Weinstock-Guttman B, Roy S, Jaworski M 3rd, Hancock L, Nizinski A, Srinivasan P, Fuchs TA, Szigeti K, Zivadinov R, Benedict RHB.

Front Aging Neurosci. 2019 May 10;11:105. doi: 10.3389/fnagi.2019.00105. eCollection 2019.

25.

Lifestyle-based modifiable risk factors in multiple sclerosis: review of experimental and clinical findings.

Jakimovski D, Guan Y, Ramanathan M, Weinstock-Guttman B, Zivadinov R.

Neurodegener Dis Manag. 2019 Jun;9(3):149-172. doi: 10.2217/nmt-2018-0046. Epub 2019 May 22.

PMID:
31116081
26.

Oxysterols and apolipoproteins in multiple sclerosis: a 5 year follow-up study.

Fellows Maxwell K, Bhattacharya S, Bodziak ML, Jakimovski D, Hagemeier J, Browne RW, Weinstock-Guttman B, Zivadinov R, Ramanathan M.

J Lipid Res. 2019 Jul;60(7):1190-1198. doi: 10.1194/jlr.M089664. Epub 2019 May 13.

PMID:
31085627
27.

Neurolymphatic biomarkers of brain endothelial inflammatory activation: Implications for multiple sclerosis diagnosis.

Yun JW, Cvek U, Kilgore PCSR, Tsunoda I, Omura S, Sato F, Zivadinov R, Ramanathan M, Minagar A, Alexander JS.

Life Sci. 2019 Jul 15;229:116-123. doi: 10.1016/j.lfs.2019.05.021. Epub 2019 May 10.

PMID:
31082401
28.

Aging and Brain Atrophy in Multiple Sclerosis.

Ghione E, Bergsland N, Dwyer MG, Hagemeier J, Jakimovski D, Paunkoski I, Ramasamy DP, Carl E, Hojnacki D, Kolb C, Weinstock-Guttman B, Zivadinov R.

J Neuroimaging. 2019 Jul;29(4):527-535. doi: 10.1111/jon.12625. Epub 2019 May 10.

PMID:
31074192
29.

Coagulation Pathways in Neurological Diseases: Multiple Sclerosis.

Ziliotto N, Bernardi F, Jakimovski D, Zivadinov R.

Front Neurol. 2019 Apr 24;10:409. doi: 10.3389/fneur.2019.00409. eCollection 2019. Review.

30.

Marijuana Use by Patients with Multiple Sclerosis.

Gupta S, Fellows K, Weinstock-Guttman B, Hagemeier J, Zivadinov R, Ramanathan M.

Int J MS Care. 2019 Mar-Apr;21(2):57-62. doi: 10.7224/1537-2073.2017-112.

31.

Vascular aspects of multiple sclerosis: emphasis on perfusion and cardiovascular comorbidities.

Jakimovski D, Topolski M, Genovese AV, Weinstock-Guttman B, Zivadinov R.

Expert Rev Neurother. 2019 May;19(5):445-458. doi: 10.1080/14737175.2019.1610394. Epub 2019 May 10.

PMID:
31003583
32.

Epidemiology and treatment of multiple sclerosis in elderly populations.

Vaughn CB, Jakimovski D, Kavak KS, Ramanathan M, Benedict RHB, Zivadinov R, Weinstock-Guttman B.

Nat Rev Neurol. 2019 Jun;15(6):329-342. doi: 10.1038/s41582-019-0183-3. Review.

PMID:
31000816
33.

Reinforcer pathology: Common neural substrates for delay discounting and snack purchasing in prediabetics.

Deshpande HU, Mellis AM, Lisinski JM, Stein JS, Koffarnus MN, Paluch R, Schweser F, Zivadinov R, LaConte SM, Epstein LH, Bickel WK.

Brain Cogn. 2019 Jun;132:80-88. doi: 10.1016/j.bandc.2019.03.003. Epub 2019 Mar 29.

34.

Leptomeningeal Contrast Enhancement Is Related to Focal Cortical Thinning in Relapsing-Remitting Multiple Sclerosis: A Cross-Sectional MRI Study.

Bergsland N, Ramasamy D, Tavazzi E, Hojnacki D, Weinstock-Guttman B, Zivadinov R.

AJNR Am J Neuroradiol. 2019 Apr;40(4):620-625. doi: 10.3174/ajnr.A6011. Epub 2019 Mar 14.

35.

Effect of Teriflunomide and Dimethyl Fumarate on Cortical Atrophy and Leptomeningeal Inflammation in Multiple Sclerosis: A Retrospective, Observational, Case-Control Pilot Study.

Zivadinov R, Bergsland N, Carl E, Ramasamy DP, Hagemeier J, Dwyer MG, Lizarraga AA, Kolb C, Hojnacki D, Weinstock-Guttman B.

J Clin Med. 2019 Mar 12;8(3). pii: E344. doi: 10.3390/jcm8030344.

36.

A Serial 10-Year Follow-Up Study of Atrophied Brain Lesion Volume and Disability Progression in Patients with Relapsing-Remitting MS.

Zivadinov R, Horakova D, Bergsland N, Hagemeier J, Ramasamy DP, Uher T, Vaneckova M, Havrdova E, Dwyer MG.

AJNR Am J Neuroradiol. 2019 Mar;40(3):446-452. doi: 10.3174/ajnr.A5987. Epub 2019 Feb 28.

PMID:
30819766
37.

Dietary and lifestyle factors in multiple sclerosis progression: results from a 5-year longitudinal MRI study.

Jakimovski D, Weinstock-Guttman B, Gandhi S, Guan Y, Hagemeier J, Ramasamy DP, Fuchs TA, Browne RW, Bergsland N, Dwyer MG, Ramanathan M, Zivadinov R.

J Neurol. 2019 Apr;266(4):866-875. doi: 10.1007/s00415-019-09208-0. Epub 2019 Feb 13.

PMID:
30758665
38.

Higher EBV response is associated with more severe gray matter and lesion pathology in relapsing multiple sclerosis patients: A case-controlled magnetization transfer ratio study.

Jakimovski D, Ramanathan M, Weinstock-Guttman B, Bergsland N, Ramasamay DP, Carl E, Dwyer MG, Zivadinov R.

Mult Scler. 2019 Feb 13:1352458519828667. doi: 10.1177/1352458519828667. [Epub ahead of print]

PMID:
30755085
39.

Comparative effectiveness of teriflunomide and dimethyl fumarate in patients with relapsing forms of MS in the retrospective real-world Teri-RADAR study.

Zivadinov R, Kresa-Reahl K, Weinstock-Guttman B, Edwards K, Burudpakdee C, Bergsland N, Dwyer MG, Khatri B, Thangavelu K, Chavin J, Mandel M, Cohan S.

J Comp Eff Res. 2019 Apr;8(5):305-316. doi: 10.2217/cer-2018-0135. Epub 2019 Feb 13.

40.

Characterization of leptomeningeal inflammation in rodent experimental autoimmune encephalomyelitis (EAE) model of multiple sclerosis.

Pol S, Schweser F, Bertolino N, Preda M, Sveinsson M, Sudyn M, Babek N, Zivadinov R.

Exp Neurol. 2019 Apr;314:82-90. doi: 10.1016/j.expneurol.2019.01.013. Epub 2019 Jan 23.

PMID:
30684521
41.

Lower total cerebral arterial flow contributes to cognitive performance in multiple sclerosis patients.

Jakimovski D, Benedict RH, Marr K, Gandhi S, Bergsland N, Weinstock-Guttman B, Zivadinov R.

Mult Scler. 2020 Feb;26(2):201-209. doi: 10.1177/1352458518819608. Epub 2019 Jan 9.

PMID:
30625030
42.

Trait Conscientiousness predicts rate of longitudinal SDMT decline in multiple sclerosis.

Fuchs TA, Wojcik C, Wilding GE, Pol J, Dwyer MG, Weinstock-Guttman B, Zivadinov R, Benedict RH.

Mult Scler. 2020 Feb;26(2):245-252. doi: 10.1177/1352458518820272. Epub 2019 Jan 7.

PMID:
30615562
43.

Atrophied brain lesion volume, a magnetic resonance imaging biomarker for monitoring neurodegenerative changes in multiple sclerosis.

Zivadinov R, Bergsland N, Dwyer MG.

Quant Imaging Med Surg. 2018 Nov;8(10):979-983. doi: 10.21037/qims.2018.11.01. No abstract available.

44.

Are Plasma Levels of Vascular Adhesion Protein-1 Associated Both with Cerebral Microbleeds in Multiple Sclerosis and Intracerebral Haemorrhages in Stroke?

Ziliotto N, Zivadinov R, Jakimovski D, Bergsland N, Ramasamy DP, Weinstock-Guttman B, Ramanathan M, Marchetti G, Bernardi F.

Thromb Haemost. 2019 Jan;119(1):175-178. doi: 10.1055/s-0038-1676346. Epub 2018 Dec 31.

PMID:
30597511
45.

The role of Epstein-Barr virus in multiple sclerosis: from molecular pathophysiology to in vivo imaging.

Guan Y, Jakimovski D, Ramanathan M, Weinstock-Guttman B, Zivadinov R.

Neural Regen Res. 2019 Mar;14(3):373-386. doi: 10.4103/1673-5374.245462. Review.

46.

Prospective phase II clinical trial of autologous haematopoietic stem cell transplant for treatment refractory multiple sclerosis.

Moore JJ, Massey JC, Ford CD, Khoo ML, Zaunders JJ, Hendrawan K, Barnett Y, Barnett MH, Kyle KA, Zivadinov R, Ma KC, Milliken ST, Sutton IJ, Ma DDF.

J Neurol Neurosurg Psychiatry. 2019 May;90(5):514-521. doi: 10.1136/jnnp-2018-319446. Epub 2018 Dec 11.

PMID:
30538138
47.

Fatigue at enrollment predicts EDSS worsening in the New York State Multiple Sclerosis Consortium.

Vaughn CB, Kavak KS, Dwyer MG, Bushra A, Nadeem M, Cookfair DL, Ramanathan M, Benedict RH, Zivadinov R, Goodman A, Krupp L, Motl RW, Weinstock-Guttman B; New York State Multiple Sclerosis Consortium.

Mult Scler. 2020 Jan;26(1):99-108. doi: 10.1177/1352458518816619. Epub 2018 Dec 3.

PMID:
30507270
48.

Brain Atrophy Is Associated with Disability Progression in Patients with MS followed in a Clinical Routine.

Ghione E, Bergsland N, Dwyer MG, Hagemeier J, Jakimovski D, Paunkoski I, Ramasamy DP, Silva D, Carl E, Hojnacki D, Kolb C, Weinstock-Guttman B, Zivadinov R.

AJNR Am J Neuroradiol. 2018 Dec;39(12):2237-2242. doi: 10.3174/ajnr.A5876. Epub 2018 Nov 22.

49.

Lower self-report fatigue in multiple sclerosis is associated with localized white matter tract disruption between amygdala, temporal pole, insula, and other connected structures.

Fuchs TA, Vaughn CB, Benedict RHB, Weinstock-Guttman B, Choudhery S, Carolus K, Rooney P, Ashton K, P Ramasamy D, Jakimovski D, Zivadinov R, Dwyer MG.

Mult Scler Relat Disord. 2019 Jan;27:298-304. doi: 10.1016/j.msard.2018.11.005. Epub 2018 Nov 9.

PMID:
30453198
50.

Assessment of mesoscopic properties of deep gray matter iron through a model-based simultaneous analysis of magnetic susceptibility and R2* - A pilot study in patients with multiple sclerosis and normal controls.

Taege Y, Hagemeier J, Bergsland N, Dwyer MG, Weinstock-Guttman B, Zivadinov R, Schweser F.

Neuroimage. 2019 Feb 1;186:308-320. doi: 10.1016/j.neuroimage.2018.11.011. Epub 2018 Nov 14.

Supplemental Content

Loading ...
Support Center